Format

Send to

Choose Destination
Curr Opin Immunol. 2011 Jun;23(3):391-8. doi: 10.1016/j.coi.2011.03.005. Epub 2011 Apr 21.

Dengue vaccines: progress and challenges.

Author information

1
Vaccines Research, WP17-2131, Merck and Company, 770 Sumneytown Pike, P.O. Box 4, West Point, PA 19486, United States. beth-ann.coller@merck.com

Abstract

With several dengue vaccine candidates progressing through clinical trials, several options for controlling this disease appear feasible. This would represent a major achievement and reflect decades of research and development activities. The challenges associated with the limited understanding of protective responses and those factors which determine disease severity remain, but with prospective studies ongoing in various dengue endemic areas and the initiation of dengue vaccine efficacy trials, immune responses are being evaluated in the context of protection and severe disease and these studies are highly likely to provide additional insights.

PMID:
21514129
DOI:
10.1016/j.coi.2011.03.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center